Autologous stem cell transplantation in patients with extragonadal germ cell tumors: A single center experience

Introduction Testicular cancer is the most common solid malignancy in men aged 15-35 years, 95% of which are germ cell tumors (GCT) (1). GCT is primarily located in the gonadal region and rarely occurs in an extragonadal area such as the mediastinum and retroperitoneum. Extragonadal GCT (EGGCT) are formed by malignant transformation of gonadal cells that have not completed their migration during embryogenesis without a gonadal primary mass in ultrasonographic evaluation (2). EGGCT accounts for 2-5% of all GCT and has an approximate incidence of 1/1,000,000 (3). Although EGGCT has similar histological, serological and cytogenetic characteristics as gonadal GCT, their behavior is different clinically and biologically. EGGCT has a worse chemosensitivity and prognosis than gonadal tumors (4,5). The treatment of EGGCT patients is similar to the treatment of gonadal GCT, and after histological separation as seminoma and non-seminoma, chemotherapy (CT) is applied according to risk classification. Surgical resection is also performed in patients with residual tumors. This multimodal treatment increases efficacy and survival (6,7). There is no standard salvage CT treatment for relapsed/refractory EGGCT patients. Autologous DOI: 10.4274/gulhane.galenos.2019.899 ORIGINAL ARTICLE

[1]  N. Hanna,et al.  High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Heng,et al.  Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres. , 2016, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[3]  E. Rajpert-De Meyts,et al.  Recent advances in understanding the etiology and pathogenesis of pediatric germ cell tumors. , 2014, Journal of pediatric hematology/oncology.

[4]  L. Einhorn,et al.  Extragonadal germ cell tumors: clinical presentation and management , 2013, Current opinion in oncology.

[5]  S. Fosså,et al.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Bremnes,et al.  High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer – a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA) , 2012, Acta oncologica.

[7]  A. Horwich,et al.  EAU guidelines on testicular cancer: 2011 update. , 2011, European urology.

[8]  H. Miyake,et al.  First‐line high‐dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors , 2007, International journal of urology : official journal of the Japanese Urological Association.

[9]  J. McKenney,et al.  Extragonadal Germ Cell Tumors: A Review With Emphasis on Pathologic Features, Clinical Prognostic Variables, and Differential Diagnostic Considerations , 2007, Advances in anatomic pathology.

[10]  S. Leyvraz,et al.  First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party , 2004, Bone Marrow Transplantation.

[11]  H. Schmoll Extragonadal germ cell tumors. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T. Chao,et al.  Extragonadal germ cell tumors in Taiwan , 2002, Cancer.

[13]  S. Fosså,et al.  Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Craig R. Nichols,et al.  Extragonadal seminoma , 2001, Cancer.

[15]  A. Horwich,et al.  Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Høie,et al.  Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94. , 1998, British Journal of Cancer.

[17]  S. Culine,et al.  [Primary mediastinal non-seminomatous germ-cell tumors: from clinics to biology]. , 1997, Bulletin du cancer.

[18]  Martin,et al.  Extragonadal germ cell tumors. A 14‐year Toronto experience , 1994, Cancer.

[19]  M. Villalona-Calero,et al.  Extragonadal Abdominal Germ Cell Cancers , 1992, American journal of clinical oncology.

[20]  N. Geller,et al.  Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features , 1991, Cancer.

[21]  W. Siegert,et al.  Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.